Bio-Path Hldgs Inc Stock Price, News & Analysis

Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced the successful completion of the safety run-in phase of Stage 2 in its Phase 2 clinical study for prexigebersen (BP1001), targeting acute myeloid leukemia (AML). Six evaluable patients received the triple combination therapy of prexigebersen, decitabine, and venetoclax, with a favorable safety profile and no dose-limiting toxicities. Notably, 83% of patients demonstrated clinical activity. The trial continues enrolling patients, aiming for significant efficacy data to petition the FDA for accelerated approval.

Bio-Path Holdings (NASDAQ: BPTH) announced a virtual poster presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting from April 10-15 and May 17-21, 2021. Dr. Maria Gagliardi will present pre-clinical studies of BP1002 combined with decitabine, targeting venetoclax-resistant cancer cells.

Presentation Details:
Date: April 10, 2021
Time: 8:30 am ET
Session: Biological Therapeutic Agents
Abstract Number: 939
Title: Efficacy of BP1002 with decitabine in resistant cells.

Bio-Path Holdings (NASDAQ:BPTH) announced its financial results for 2020, reporting a net loss of $10.9 million, or $2.83 per share, compared to a loss of $8.6 million in 2019. Research and development expenses rose to $6.6 million from $4.6 million, reflecting increased clinical activity. The company raised $13 million through a public offering and secured a new U.S. patent for its DNAbilize® platform technology. Bio-Path commenced a Phase 1 trial for BP1002.

Bio-Path Holdings (NASDAQ: BPTH) will host a live conference call on March 10, 2021, at 8:30 a.m. ET to report its financial results for 2020 and provide a business overview. The call can be accessed at (844) 815-4963 domestically or (210) 229-8838 internationally, using conference ID 6296959. Additionally, a live audio webcast will be available on the company's website. Bio-Path focuses on developing its proprietary DNAbilize® technology for targeted nucleic acid cancer treatments. Key products include prexigebersen, in Phase 2 trials for blood cancers, and BP1002, under evaluation for lymphoma.

Bio-Path Holdings, Inc. (Nasdaq:BPTH) has successfully closed its public offering of 1,710,600 shares of common stock at $7.60 each, raising approximately $13.0 million before fees. Proceeds are intended for working capital and general corporate purposes. Roth Capital Partners served as the sole placement agent for the offering. The shares were offered under an effective shelf registration statement, and the company is developing novel cancer treatments utilizing its DNAbilize® technology, targeting specific protein pathways.

Bio-Path Holdings, Inc. (Nasdaq:BPTH) announced a public offering of 1,710,600 shares at $7.60 each, raising approximately $13 million before expenses. The offering is expected to close on February 18, 2021. Proceeds will be utilized for working capital and general corporate purposes. Roth Capital Partners is the sole placement agent for this offering. A registration statement related to the shares has been declared effective by the SEC. Bio-Path is advancing its DNAbilize® technology aimed at developing targeted cancer drugs, including prexigebersen currently in Phase 2 studies.

Bio-Path Holdings (Nasdaq: BPTH) has announced its intention to offer and sell shares of its common stock in a public offering, subject to market conditions. Roth Capital Partners is the sole placement agent for this offering. The net proceeds will be utilized for working capital and corporate purposes. A preliminary prospectus will be filed with the SEC as part of an effective shelf registration statement declared on June 5, 2019. This offering may present investors with new opportunities, although specific terms and timing remain uncertain.

Bio-Path Holdings (NASDAQ:BPTH) announced the granting of U.S. Patent No. 10,898,506, enhancing protection for its DNAbilize technology. This patent covers P-ethoxy nucleic acids for liposomal formulation, strengthening the company's intellectual property. Additionally, a notification for U.S. Patent No. 10,927,379 related to its lead product prexigebersen is set to issue on February 23, 2021. The new patents bolster Bio-Path's competitive edge and safeguard ongoing clinical trials, particularly in treating acute myeloid leukemia.

Bio-Path Holdings (NASDAQ:BPTH) has initiated a Phase 1 clinical trial for BP1002, targeting Bcl-2 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia (CLL).

The trial aims to enroll six patients, assessing safety, tolerability, and pharmacokinetics over a four-week treatment period. BP1002 has demonstrated potent inhibition of Bcl-2 in preclinical studies, potentially offering a new therapy for patients resistant to existing treatments like venetoclax. With notable unmet medical needs in this area, Bio-Path anticipates preliminary efficacy results.